G protein-coupled receptors (GPCRs) represent the largest family of cell surface molecules involved in signal transduction. Surprisingly, open reading frames for multiple GPCRs were hijacked in the process of coevolution between Herpesviridae family viruses and their human and mammalian hosts. Virally encoded GPCRs (vGPCRs) evolved as parts of viral genomes, and this evolution allowed the power of host GPCR signaling circuitries to be harnessed in order to ensure viral replicative success. Phylogenetically, vGPCRs are distantly related to human chemokine receptors, although they feature several unique characteristics. Here, we describe the molecular mechanisms underlying vGPCR-mediated viral pathogenesis. These mechanisms include constitutive activity, aberrant coupling to human G proteins and β-arrestins, binding and activation by human chemokines, and dimerization with other GPCRs expressed in infected cells. The likely structural basis for these molecular events is described for the two closest viral homologs of human GPCRs. This information may aid in the development of novel targeted therapeutic strategies against viral diseases.
VIRALLY ENCODED GPCRs
Viral genomes have evolved to exploit an extraordinary repertoire of tools designed to ensure successful infectivity and propagation. Thus, it is not surprising that human GPCRs have emerged as critical players in viral entry, modulation of the host immune response, and promotion of host cell proliferation or death (4) . These GPCR-regulated processes ultimately ensure viral replicative success, thereby contributing to viral pathogenesis. Remarkably, many human viruses also harbor open reading frames that encode GPCRs in their viral genomes; consequently, these viruses can harness the power of GPCR signaling in the host cells and organisms. The family of human herpesviruses encodes multiple GPCRs. Most virally encoded GPCRs (vGPCRs) have been hijacked and have evolved from the comparatively small family of chemokine receptors (Figure 1) . The human herpesvirus-4 (HHV-4), also known as the Epstein-Barr virus (EBV), encodes a receptor termed BILF1, whereas the human cytomegalovirus (HCMV, also known as HHV-5) expresses multiple vGPCRs, including US28, US27, UL33, and UL78. Human herpesvirus-6 (HHV-6) and its close relative human herpesvirus-7 (HHV-7) each encode two vGPCRs, U12 and U51, whereas the Kaposi's sarcoma-associated herpesvirus (KSHV, also known as HHV-8) encodes a single receptor termed ORF74 (more commonly known as KSHV vGPCR). Nonhuman viruses, including Herpesviridae and Poxviridae family members, also express open reading frames for vGPCRs, most of which are highly related to chemokine receptors. Among them, the most widely studied is the murine herpesvirus-68 (MHV-68), whose ORF74 encodes a vGPCR highly related to KSHV vGPCR and hence has been used to investigate the role of the latter in viral replication in vivo (5) . Similarly, the murine cytomegalovirus (MCMV) encodes a vGPCR termed M33, which is closely related to US28 and therefore has served as an excellent model for studying the effects of M33 deletion or impairment mimicking US28 deficiency on viral replication in vivo (6) . Among the poxviruses, the swinepoxvirus expresses a chemokine receptorrelated vGPCR termed K2R open reading frame or C3L; the capripoxvirus encodes two vGPCRs, the Q2/3L open reading frame and LSDV01; and the avipoxvirus fowlpox virus encodes more than four vGPCRs. Although we do not review the function of nonhuman vGPCRs, the widespread 
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Figure 1
Phylogenetic tree of Herpesviridae-encoded GPCRs in the context of their most closely homologous human GPCRs. vGPCRs are distantly related to chemokine receptors and share many of the human chemokine ligands. The two viral receptors with closest homology to human GPCRs are KSHV vGPCR (also known as ORF74), which has 26% sequence identity to CXCR2, and CMV US28, which has 36% sequence identity to CX3CR1. This level of homology enables the construction of 3D models for KSHV vGPCR and CMV US28 based on the X-ray structure of human chemokine receptor CXCR4 (7, 8) . For all other vGPCRs, the farther phylogenetic distance to human GPCRs allows tentative conclusions about general principles of activation and ligand binding preferences but not accurate homology modeling. Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; GPCR, G protein-coupled receptor; HHV, human herpesvirus; KSHV, Kaposi's sarcoma-associated herpesvirus; vGPCR, virally encoded G protein-coupled receptor.
the chronic release of these inflammatory molecules and has served as a model for tumor-and inflammation-induced angiogenesis (10, 12) . KSHV is a γ-2-herpesvirus that is related to Herpesvirus saimiri and EBV. It was first isolated from human AIDS-KS lesions by Yuan Chang, Patrick Moore, and colleagues (13) and later found to be associated with all four forms of KS [classic, AIDS-associated, endemic (African), and iatrogenic] (12, 14) . In addition, KSHV has also been identified as the etiological agent for two lymphoproliferative disorders: primary effusion lymphoma and multicentric Castleman's disease (see vGPCR and KSHV-Associated Lymphoid Malignancies, below) (15) .
Like other members of the herpesvirus family, KSHV remains latent in the majority of infected cells, with gene expression limited to a few viral genes that maintain the latent state (14) . A small percentage of KSHV-infected cells spontaneously exit latency to enter the lytic cycle; this process is accompanied by the expression of viral replicative and structural genes, resulting in the lysis of the host cell and the release of a new progeny of infective virions. The KSHV genome contains more than 80 open reading frames, including genes required for viral replication and assembly (16) . Unlike most tumor viruses, KSHV encodes more than a dozen homologs to mammalian proteins that have likely been pirated by KSHV from its cellular host. These genes play an important role in regulating host cell immune function, enhancing host cell survival and proliferation, inducing cytokine dysregulation, and promoting angiogenesis (10) . Among the KSHV proteins that contribute to cytokine upregulation in KS, KSHV vGPCR is unique in that it is both transforming and proangiogenic (17) .
Molecular Determinants of KSHV vGPCR Constitutive Activity
KSHV vGPCR is closely related to the CXC family of chemokine receptors-in particular, to the CXCR1 and CXCR2 receptors for interleukin-8 (IL-8/CXCL8) (18, 19) . In addition to being activated upon agonist binding, KSHV vGPCR exhibits ligand-independent constitutive activity in a variety of cell-based biochemical assays. This constitutive activity arises from several unique structural characteristics that make KSHV vGPCR distinct from other chemokine receptors (Figure 2) . KSHV vGPCR has a network of residue substitutions at positions that are highly conserved in other GPCRs and that may be involved in stabilization of the inactive state and in agonist-induced conformational transition from the inactive to the active state. Whereas many individual substitutions are expected to destabilize the protein and interfere with its proper folding, Molecular modeling elucidates the determinants of constitutive activity and ligand binding in the two vGPCRs with the highest extent of homology to human chemokine receptors. (a) Residue comparison in key positions among CMV US28, KSHV vGPCR, and human class A GPCRs. The key residues that are believed to be involved in the active-to-inactive transition are conserved between US28 and human GPCRs but not in KSHV vGPCR. (b-d ) The structure of (b) hCXCR4 and the 3D models of the two vGPCRs, (c) KSHV vGPCR and (d) CMV US28. The proteins are viewed from the extracellular side perpendicular to the membrane plane. (c) The nonconservative substitutions lead to a gain in interhelical contacts in the extracellular parts of TMs II, III, and VII of KSHV vGPCR with concurrent loss of some important interactions in the intracellular parts of these helices (e.g., hydrogen bonding of N7.49V) and in TM VI (e.g., W6.48C). Together, these substitutions result in a high level of constitutive activity of KSHV vGPCR. (d ) The determinants of activation of US28 resemble those of most human GPCRs, with the exception of A114 in position 3.35 (Ballesteros-Weinstein notation). (e-g) The overall shapes of the binding pockets and the electrostatic properties of (e) hCXCR4, ( f ) KSHV vGPCR, and ( g) CMV US28. The receptors are shown in lateral view and identical orientation with the front of the skin clipped for clarity. The skins are colored by electrostatic properties (red indicates negatively charged; blue, positively charged). The models were constructed and analyzed using the Molsoft ICM molecular modeling package (20, 21) . Abbreviations: CMV, cytomegalovirus; GPCR, G protein-coupled receptor; hCXCR4, human chemokine receptor CXCR4; KSHV, Kaposi's sarcoma-associated herpesvirus; TM, transmembrane helix; vGPCR, virally encoded G protein-coupled receptor.
pairs or larger groups of substitutions observed in KSHV vGPCR appear to have a compensatory effect on one another. Consequently, the general stability and folding of KSHV vGPCR are not compromised; instead, its basal conformational equilibrium is strongly shifted toward the active state, hence resulting in constitutive activity and efficient coupling to multiple human G proteins.
The substitutions in KSHV vGPCR that stand out as having structural impact include the triplet of residues at positions 2.50, 3.39, and 7.49 (Ballesteros-Weinstein notation) (22) , which link transmembrane helices (TMs) II, III, and VII via a network of hydrogen bonds. Although found in most receptors as DSN, DGN, DCN, or DEN (one-letter amino-acid codes C, D, E, G, N, S, and V stand for cysteine, aspartate, glutamate, glycine, asparagine, serine, and valine, respectively), this triplet is SDV (S93, D132, and V310) in KSHV vGPCR (Figure 2) . This "swap" disrupts the water-mediated hydrogen bonding network and results in the activated conformation of helix VII. Another pair of residues that typically mediates interhelical hydrogen bonding interactions is located at positions 3.35 (N in 29% of receptors; G, S, or C in others) and 7.45 (N in 67% of receptors; H or S in the remaining ones). Both these highly conserved residues are substituted by tyrosines in KSHV vGPCR: Y128 and Y306 (Figure 2) . The two bulky aromatic residues greatly modify the nature and the strength of the interhelical interaction, which, in KSHV vGPCR, acquires a hydrophobic packing component in addition to the hydrogen bond functionality that is preserved in the phenol groups. The role of a Tyr at position 3.35 is further corroborated by the fact that similar mutations in other GPCRs render them constitutively active (23) .
CMV US28

BallesterosWeinstein
Residue 6.48, which is a W or a Q in most class A GPCRs and which participates both in stabilization of the inactive state via the water-mediated hydrogen bonding network connecting it to D2.50, and in activation transition via a change in the steric environment, is substituted with a Cys in KSHV vGPCR. The unusual residue at position 7.42 partially compensates for this substitution. Whereas in the majority of receptors, 7.42 is small (G, A, S, or C), KSHV vGPCR has Q303, which not only partially fills the empty space created by [WQ]6.48C substitution but also makes up for the associated loss of interhelical hydrogen bonds. However, these gained interactions do not stabilize the inactive state of helix VI; instead, they restrict the rotation of helix VII and likely stabilize it into its activated state.
Finally, basic residues are present in multiple positions at the intracellular end of TM VI (6.30-6.34, 246-RRKVR-250) as well as the intracellular ends of TMs III and IV (3.50, 4.37-4.38, R143, 156-KK-157), but the one and only negatively charged counterion in the region is eliminated in KSHV vGPCR by the [ED]3.49V substitution in the DRY motif (V142). Although this feature may have a profound effect on the basal equilibrium, whether it preferentially stabilizes active versus inactive state or vice versa is not clear; alternatively, it may simply make the G protein binding more favorable. Introducing a V142D mutation in KSHV vGPCR results in ∼70% increase in its constitutive activity, whereas a double D83A/V142D mutation makes it 510% more active in signaling assays based on phospholipase C activation (24) . Concurrent with the [ED]3.49V substitution, KSHV vGPCR also has a L146 in position 3.53, which is bulkier than the commonly occurring A, S, C, and V and is likely to contribute to either the conformational equilibrium or the G protein binding.
This detailed analysis of the amino acid substitutions in KSHV vGPCR with respect to highly conserved residues in the GPCR family suggests that this particular virally encoded receptor has evolved to gain multiple molecular changes that enhance its basal activity and G protein-coupling efficiency even in the absence of any bound ligand. Although these predictions based on the structural features of KSHV vGPCR warrant further investigation, multiple studies have defined the role of individual receptor residues in chemokine binding and signaling activity, which can guide the search for clinically relevant KSHV vGPCR allosteric modulators or inhibitors that halt its constitutive activity and transforming potential (24) (25) (26) (27) (28) .
Pharmacology of KSHV vGPCR
KSHV vGPCR exhibits efficacious, ligand-independent constitutive activity. However, certain chemokines can interact with KSHV vGPCR and modulate its function; this modulation depends on posttranslational modifications by sulfate groups of tyrosine residues within the vGPCR N-terminal extracellular domain (29) . For example, Groα/CXCL1 and Groγ/CXCL3 can further activate vGPCR and act as full agonists; CXCL8/IL-8 is a neutral ligand and low-potency agonist; Groβ/CXCL2 acts as a partial agonist; and inducible protein-10 (IP-10/CXCL10) and SDF-1α/CXCL12 can inhibit KSHV vGPCR signaling and act as inverse agonists (30, 31) . KSHV also encodes a chemokine ligand, vMIP-II, that inhibits signaling by KSHV vGPCR, thereby providing the virus with a control mechanism to modulate the activity of this receptor (31, 32) . In general, KSHV vGPCR prefers neutral or slightly acidic chemokines, consistent with the charge distribution in its binding pocket (Figure 2f ). The high level of chemokine promiscuity distinguishes KSHV vGPCR from CXCR1, CXCR2, CXCR4, and other human chemokine receptors, as the latter typically bind only a restricted number of ligands.
vGPCR as the KSHV Tumor-Initiating Oncogene
Compelling evidence supports an essential role for vGPCR in the initiation and progression of KS in vivo. vGPCR generates vascular tumors remarkably similar to human KS when expressed in mice using an endothelial-specific (TIE2-tva) gene transfer system (33) . Three other vGPCR transgenic models as well as an animal model of virally induced KS also support a role for vGPCR in Kaposi's sarcomagenesis (34) (35) (36) (37) . Analysis of murine vGPCR-induced tumors reveals expression of this receptor in only a few tumor cells and upregulation of a large number of inflammatory and angiogenic molecules (cytokines, chemokines, and growth factors), which is similar to what occurs in human KS and suggestive of a paracrine mechanism for vGPCR oncogenesis (33) . Conditional transgenic expression of vGPCR has revealed the key role of continued vGPCR expression in the progression of the KS-like phenotype (36) . Together, these findings implicate vGPCR as a critical element in KS pathogenesis and suggest that strategies to block its function may represent a novel approach for the treatment of KS.
A Complex Signaling Network Underlies the Potent Sarcomagenic Potential of KSHV vGPCR
vGPCR enhances the activity of a complex signaling network, whose contribution to the oncogenic and proangiogenic activities of this receptor is beginning to be unraveled (Figure 3 ). For example, vGPCR stimulates the PI3K/AKT pathway in endothelial cells, thereby protecting them from apoptosis (38) . Therefore, vGPCR might use this pathway to promote the survival of KSHVinfected endothelial cells. Interestingly, vGPCR can also activate AKT in an autocrine manner by upregulating the expression of the vascular endothelial growth factor (VEGF) receptor KDR2 (39) and by promoting the concomitant release of VEGF (17, 39) , which activates AKT through the VEGF receptor. vGPCR-expressing endothelial cells can then induce activity of AKT in neighboring endothelial cells through the release of VEGF and other cytokines and chemokines by a paracrine mechanism (40) . Direct and paracrine AKT activation of the TSC2/mTOR pathway is necessary and sufficient for vGPCR oncogenesis (41) .
Although the different downstream mechanisms by which vGPCR-mediated mTOR drives vGPCR sarcomagenesis are still unclear, one includes the dramatic amplification of VEGF secretion. This occurs through the activation by vGPCR cytokines of multiple kinases including AKT, extracellular signal-regulated kinase (ERK), p38, and IKKβ, all of which can ultimately converge in TSC/mTOR activation and hypoxia-inducible factor (HIF) upregulation in (neighboring) non-vGPCR-expressing cells (42) . Another novel proangiogenic and protumorigenic factor that is highly upregulated through vGPCR direct and paracrine HIF activation is Angiopoietin-like 4 (ANGPTL4), which is involved in tumor progression and metastasis through regulation of endothelial cell-cell junctions (43, 44) . ANGPTL4 is highly upregulated in vGPCR murine tumors and human KS lesions and is equivalent to VEGF in its regulation of angiogenesis and vascular permeability in KS (43, 44 ORF74 of KSHV encodes a vGPCR (KSHV vGPCR) that utilizes diverse but interdependent strategies to promote dysregulated angiogenesis and endothelial cell transformation of both expressing and recruited (bystander) endothelial cells, thereby promoting Kaposi's sarcomagenesis. Abbreviations: KSHV, Kaposi's sarcoma-associated herpesvirus; vGPCR, virally encoded G protein-coupled receptor.
the AKT/mTOR/HIF axis or HIF downstream targets may represent mechanism-based therapies to treat patients with KS (41) (42) (43) (45) (46) (47) (48) . In addition, PI3Kγ, a PI3K isoform with restricted tissue distribution, is also strictly required for signaling from the KSHV-encoded GPCR oncogene to AKT/mTOR, suggesting that PI3Kγ may represent an alternative molecular target for therapeutic intervention in KS (49) .
The transforming, prosurvival, and angiogenic effects of vGPCR also highly depend on its ability to stimulate mitogen-activated protein kinases (MAPKs) and, consequently, the activity of transcription factors that are regulated by these kinases. vGPCR induction of VEGF expression depends on ERK and p38, which phosphorylate HIF-1α, thereby increasing transcription from a HIF-responsive element within the VEGF promoter (50) . vGPCR can also activate the AP-1, NF-κB, CREB, and NFAT transcription factors (17, 38, (51) (52) (53) (54) . AP-1 and NF-κB can stimulate the expression of proinflammatory cytokines such as IL-1β, IL-2, IL-4, IL-6, TNF-α, CCL3/macrophage inflammatory protein-1 (MIP1), and IL-8/CXCL8, as well as bFGF-all 17.8 of which are important mediators in KS (10) . Interestingly, vGPCR stimulates an NF-κB gene expression signature in endothelial cells that express vGPCR or in nonexpressing cells exposed to vGPCR secretions (55) . These events may help propagate a vGPCR-initiated paracrine signaling network to the surrounding and even distant endothelial cells, thereby promoting their unrestricted growth. Furthermore, because small guanosine triphosphate (GTP)-binding proteins represent critical links between GPCRs and nuclear transcription factors, the involvement of members of the Rho family of small guanosine triphosphatases (GTPases) in vGPCR-induced transcriptional regulation has been investigated. These experiments revealed that vGPCR activates the small G protein Rac1 (51) . Preventing vGPCR-promoted activation of Rac1 blocks the stimulation of the transcriptional activity of NF-κB, AP-1, and NFAT and inhibits cytokine secretion in vitro and vGPCR sarcomagenesis in vivo (51) . Moreover, expression of activated Rac1 is sufficient to generate murine tumors that are similar to KS (51, 56 ). An animal model with endothelial cell-specific deletion of Rac1 has revealed an essential role for this GTPase in endothelial cell function and vascular development, corroborating a role for Rac1-mediated pathways in aberrant neovascularization (57) .
vGPCR and KSHV-Associated Lymphoid Malignancies
In addition to KS, vGPCR might have a distinct role in two other KSHV-associated malignancies: primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD), two rare B cell lymphomas with increased incidence in AIDS patients (10, 15) . The gene expression profile of vGPCR-expressing B cells is quite different from that observed in endothelial cells, suggesting that signaling by this receptor may make different contributions to the pathogenesis of KSHV-related endothelial and lymphoproliferative lesions (58) . Even so, in PEL-derived cell lines, vGPCR also activates ERK and p38, as well as the transcription factors AP-1, NF-κB, CREB, and NFAT (59) . The activation of AP-1 and CREB is mediated cooperatively by the Gα q -ERK and Gα i -PI3K signaling pathways. However, unlike in other cell types, NF-κB activation by vGPCR seems not to be mediated by Gα i or by PI3K-AKT (60); instead, it may require Rac1 (51). Conversely, NFAT activation in lymphocytes requires signaling through the PI3K-AKT pathway to glycogen synthase kinase-3 (GSK3) and results in increased expression of NFAT-dependent cell surface molecules (such as CD25, CD29, and the FAS ligand), proinflammatory cytokines (such as IL-2 and IL-4), and proangiogenic factors [such as granulocyte/macrophage colony-stimulating factor (GM-CSF) and TNF-α] (61). Therefore, vGPCR might upregulate the expression of lymphocyte chemoattractants and mitogens that promote B cell recruitment and proliferation in KSHVinduced lymphoproliferative disorders.
In addition to promoting the secretion of VEGF, vGPCR also augments the expression of another KSHV gene product, vIL-6, in KSHV-infected PEL cells (59) . This IL-6 homolog has sequence similarity (25% amino acid identity) to human IL-6, a cytokine that enhances B cell survival and proliferation (10) . Similar to human IL-6, vIL-6 upregulates intracellular signaling pathways by stimulating a transmembrane protein coreceptor, gp130, which is shared by other cytokines. However, whereas human IL-6 requires both its specific receptor, gp80, and the gp130 coreceptor, vIL-6 bypasses the requirement for gp80 by binding directly to the gp130 subunit (9, 12, 62) . In both cases, activation of gp130 stimulates Janus kinase ( JAK), which phosphorylates transcription factors of the signal transducer and activator of transcription (STAT) family (63) . PEL-derived cell lines depend on this viral cytokine for proliferation and survival, implying that vGPCR might indirectly promote the development of PEL and MCD through the upregulation of vIL-6. vIL-6 does not seem to have a major role in KS. The complex interplay among viral and host cell genes probably contributes to the diversity and complexity of KSHV-associated diseases.
HUMAN CYTOMEGALOVIRUS VGPCRS Human Cytomegalovirus
Human cytomegalovirus (HCMV) is a widespread herpesvirus, as reflected by the presence of antibodies against HCMV proteins in 50-95% of the population (64) . In most immunocompetent subjects, this virus causes asymptomatic or subclinical infections. However, in immunocompromised individuals, HCMV infection can cause severe manifestations, such as pneumonitis or obliterative bronchiolitis. HCMV is also the leading cause of congenital viral infection; it can be transmitted during pregnancy from the mother with primary (and also recurrent) infection to the fetus (65) . HCMV infection has been linked to glioma pathogenesis (66) and is detected in arterial tissues in atherosclerotic patients, where it promotes arterial smooth muscle cell focal proliferation (67) . Among the HCMV-encoded proteins, four GPCRs-US28, UL33, US27, and UL78-are likely candidates for involvement in HCMV-induced pathogenesis (67, 68) .
US28
US28 is the most widely characterized GPCR encoded by HCMV. It is activated by a broad array of chemokines and is able to induce smooth muscle cell migration, possibly contributing to accelerated vascular disease. Extensive research efforts are dedicated to develop therapeutic agents targeting this viral receptor.
Pharmacology of US28.
US28 is a homolog of CCR1, CCR2, and CX3CR1 that was identified as a promiscuous calcium-mobilizing receptor for chemokines such as CCL5/RANTES, macrophage inflammatory protein-1 α (MIP1-α), macrophage inflammatory protein-1 β (MIP1-β), monocyte chemoattractant protein-1 (MCP-1), and CX3CL1/fractalkine (69, 70) . Its binding pocket closely resembles those of several human chemokine receptors in terms of shape and residue property distribution (Figure 2g) . Recent efforts have shown that even though US28 is a constitutively active GPCR, it is druggable, as it can be inhibited by small nonpeptidergic molecules such as VUF2274, which behaves as a full inverse agonist for it (71) . VUF2274 also inhibits 60% of the US28-mediated HIV entry. These initial studies sparked the search for new pharmacological compounds targeting vGPCRs, leading to the synthesis and pharmacological characterization of many additional novel US28 inhibitors, which hold promise for future potential clinical applications (72, 73) .
Molecular determinants of US28 vGPCR constitutive activity.
Unlike KSHV vGPCR, US28 represents a fairly "classical" GPCR in which the determinants of activation are fully conserved (Figure 2a) . This trait, however, does not preclude it from being constitutively active and therefore akin to human GPCRs for which basal ligand-independent activity and inverse agonism have been described (74, 75) . A possible reason for the constitutive activity of US28 is the small hydrophobic residue (A114) in position 3.35 of the transmembrane helix III that does not support the sufficient interhelical interactions between TM domains II, III, and VII (Figure 2c) . Whereas among most GPCRs, the preferred residue at this position is N3.35, Ala or Val are observed in several human GPCRs with documented constitutive activity, including muscarinic M 2 and M 3 receptors and histamine receptor H 1 . An N119A mutation at the identical position of CXCR4 gives this nonconstitutively active receptor detectable basal, agonist-independent activity (76); similar results are observed for AT 1A angiotensin II receptors (77) and α 1B adrenergic receptors (23) . Another residue that may correlate with constitutive activity is A77 in position 2.48 (normally a larger hydrophobic residue). Although facing the lipid bilayer, this residue affects the basal signaling in some human receptors (78) as well as in KSHV vGPCR (27) . Additional mutagenesis studies will be necessary to confirm these predictions.
Signaling by US28. US28 is an example of a constitutively active receptor (79, 80) . The surface expression and β-arrestin-dependent endocytosis of US28 is regulated by constitutive receptor phosphorylation in C-terminal serine and threonine residues (81) (82) (83) . The deletion of the US28 C terminus results in reduced constitutive endocytosis and enhanced signaling capacity. The receptor activity can be further enhanced by certain CC chemokines, including RANTES and MCP-1. Because of its high affinity to human chemokines, US28 can modify the chemokine environment of infected cells through sequestration of those chemokines, which downregulates their extracellular levels, thereby facilitating immune evasion at sites of infection and contributing to the latent presence of the virus (84) (85) (86) .
Like KSHV vGPCR, US28 activates numerous signaling cascades (Figure 4) . US28 activates NF-κB through βγ dimers that are released from Gα q/11 and activates CREB through p38 (80) , thus suggesting that US28 may regulate various transcription factors through G protein-initiated signaling routes that control MAPKs. NFAT and serum response factor (SRF) are other transcription factors activated by US28 (87, 88) . Activation of SRF is mediated by Gα q proteins that likely act via RhoA. However, the stimulatory effect of US28 and Gα q appears to be independent of phospholipase C β (PLC-β) activation and is sensitive to inhibition by Gα 16 , which may compete for Gα q binding and uncouple it from US28 (88). US28 appears to have a more promiscuous coupling selectivity, as cellular migration is increased by the expression of Gα 12/13 proteins. These G proteins, in turn, may enhance the ability of US28 to activate RhoA/ROCK, which depends on US28 stimulation with CCL5/RANTES (89) .
Signaling capacity of US28 in cell migration. US28 promotes the migration of infected cells toward CC-chemokine-secreting tissues, thereby assisting virus dissemination. Interestingly, US28-mediated cell migration provides a molecular basis for the observations that link HCMV to the acceleration of vascular disease (90) . Enhanced cellular migration is observed in HCMV-infected primary arterial smooth muscle cells (SMCs) but not in SMCs infected by mutants of HCMV that lack US28-although this latter effect can be rescued by expression of US28 but not a cellular homolog. US28 signals through Src and focal adhesion kinase (FAK); this activity is necessary for US28-mediated SMC migration (91) . In the presence of CCL5/RANTES, US28 stimulates the production of a FAK-Src kinase complex, and Src coimmunoprecipitates with US28 in a ligand-dependent manner. This association occurs earlier than the formation of the FAK-Src kinase complex, suggesting that US28 activates Src before it activates FAK. US28 binding to CCL5/RANTES also promotes the formation of a Grb2-FAK complex, which is blocked by the Src inhibitor PP2, further highlighting the critical role of Src in US28 activation of FAK.
Collectively, these findings demonstrate that activation of FAK and Src plays a critical role in US28-mediated signaling and SMC migration. This pathway may contribute to the resulting infiltration of SMCs into the innermost membrane of the vessel, which can then cause the narrowing of the large blood vessels and hence influence vascular pathology.
A potential role for US28 signaling in tumorigenesis. Several studies implicate a role for US28 in tumorigenesis (92, 93) . US28 expression induces a proangiogenic and transformed phenotype by upregulating the expression of VEGF and enhancing cell growth and cell cycle progression (93) . Constitutive activity is important for tumor development because cells expressing an uncoupled, constitutively inactive mutant of US28-compared with US28-expressing cells-exhibit delayed and attenuated tumor formation in nude mice. Studies that include microarray analysis suggest 17.11 Changes may still occur before final publication online and in print 
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Figure 4
The US28 CMV vGPCR utilizes a complex intracellular network to promote angiogenesis, migration, and aberrant cell growth. US28 acts as a constitutively active GPCR that activates multiple signaling pathways, either in the absence of agonist binding or when bound to its ligands. Abbreviations: CMV, cytomegalovirus; GPCR, G protein-coupled receptor; vGPCR, virally encoded G protein-coupled receptor.
that US28 influences the production of VEGF by promoting upregulation of COX-2 through NF-κB (92) . Indeed, pharmacological inhibition of COX-2 with celecoxib can inhibit the angiogenic activity and tumorigenesis of US28-transfected murine fibroblasts, implying that the development of HCMV-related proliferative diseases may involve the activation of COX-2 by US28 and the consequent production of lipid inflammatory mediators (92) . US28 also can induce an invasive and angiogenic phenotype in glioblastoma multiforme (GBM), a tumor associated with HCMV infections (93, 94) . In either uninfected GBM cells or neural progenitor cells that are thought to be GBM precursor cells, HCMV infection or US28 overexpression promoted secretion of biologically active VEGF and activated cellular proteins that promote glioma growth and invasion, including phosphorylated STAT3 (p-STAT3) and endothelial nitric oxide synthase (eNOS) (94) . This invasive phenotype was further enhanced by CCL5/RANTES, a US28 ligand associated with poor outcome in patients with GBM. Conversely, RNA interference-mediated knockdown of US28 in human glioma cells persistently infected with HCMV leads to an inhibition of VEGF expression and glioma cell invasion in response to CCL5/RANTES. US28 colocalizes in GBM with markers of angiogenesis and in-flammation, including VEGF, p-STAT3, COX-2, and eNOS (94) . The emerging picture from these studies and other findings (95) is that US28 expression from the HCMV genome contributes to GBM pathogenesis by inducing an invasive, angiogenic phenotype. This possibility requires further clinical evaluation, as targeting US28 may have therapeutic benefits in some GBM patients. Other studies suggest that US28 mediates proliferative signaling by activating the IL-6-STAT3 axis (96) , primarily by promoting the release of IL-6 through the activation of NF-κB in model cellular systems as well as in HCMV-infected cells. Glioblastoma specimens from patients demonstrate colocalization of US28 and p-STAT3 in the vascular niche of these tumors, suggesting that US28 may help establish a positive feedback loop that increases tumor growth through activation of the IL-6-STAT3 signaling pathway.
Recent evidence underscores the potential role of US28 in tumor development (97) : Transgenic mice in which US28 expression was targeted to intestinal epithelial cells (IECs) develop intestinal neoplasia. US28 expression in IECs inhibited GSK-3β, thus promoting β-catenin accumulation and increasing the expression of Wnt target genes involved in the control of cell proliferation. These mice showed a hyperplastic intestinal epithelium and developed adenomas and adenocarcinomas. When exposed to an inflammation-driven tumor model (azoxymethane/dextran sodium sulfate), these mice develop a higher tumor burden than do control littermates. As transgenic coexpression of the US28 ligand CCL2 (an inflammatory chemokine) increased IEC proliferation and tumor burden, it is speculated that the oncogenic activity of US28 is further modulated by local inflammatory factors.
UL33
UL33 is a glycoprotein whose gene is conserved among all β-herpesviruses. UL33 might not bind chemokines, but it can activate several signaling cascades in a ligand-independent manner, including PLC-β through Gα q proteins and partially through Gα i/o (71) . In addition, UL33 constitutively upregulates CREB-mediated transcription by coupling to Gα i/o and Gα s , thereby regulating intracellular levels of cAMP. UL33 can also enhance CRE activation through the Rho/p38 pathway, via Gβγ. Infection with an UL33-deficient variant of HCMV confirmed that HCMV's CRE activation depends, at least in part, on UL33 expression (71) . Activation of CRE, in turn, might promote the expression of molecules that stimulate cell growth, such as cyclin D. It is tempting to speculate that HCMV US28 and UL33 may contribute to the observed transformation of SMCs in atherosclerosis by activating ERK-and p38-dependent proliferative signaling pathways. However, a definitive role for these pathways in HCMV-induced SMC proliferation remains unclear.
US27
HCMV US27 is a heterogeneously N-glycosylated receptor that is expressed during the late phase of replication and that does not show constitutive activity (80, 98, 99) . No cellular ligands have been identified for this viral receptor, possibly owing to the presence in the C-terminal domain of the HCMV US27 protein of a di-leucine endocytic sorting motif that is both necessary and sufficient for intracellular localization (100) . Recent data show that US27, and also UL33 and UL78, can colocalize and heteromerize with US28 in vitro (101) . Furthermore, HCMV mutants lacking US27 rely primarily on direct cell-to-cell spread, indicating that US27 may act at a late stage of the HCMV replication cycle to support efficient spread of the virus by the extracellular route (102).
UL78
HCMV UL78 lacks constitutive signaling activity but can colocalize and heteromerize with US28 (80, 98, 101) . Indeed, whereas the constitutive activation of the US28-mediated Gα q /PLC pathway is not affected by receptor heteromerization, UL33 and UL78 are able to silence US28-mediated activation of the transcription factor NF-κB. This finding suggests that the interaction between receptors may have an important regulatory capacity in the function of US28 and, as a consequence, may ultimately impact the HCMV viral life cycle (101) . Conversely, another study shows that this receptor may not be essential for virus replication in fibroblasts or in ex vivo-cultured sections of human renal arteries (103) .
EPSTEIN-BARR VIRUS BILF1
In 1961, Denis Burkitt described a childhood B cell malignancy in Uganda, now known as Burkitt's lymphoma, whose viral etiology he suspected to be closely associated with malaria (104) . In 1965, Tony Epstein and Yvonne Barr identified herpesvirus particles by electron microscopy in Burkitt's lymphoma cells. This virus was distinct from other previously described herpesviruses and was named Epstein-Barr virus (EBV) or human herpesvirus 4 (HHV-4) (105) . We now know that EBV is associated with infectious mononucleosis and multiple human malignancies, including nasopharyngeal carcinoma, gastric carcinoma, almost half of the cases of Hodgkin's lymphoma, and B cell lymphoma in immunocompromised patients (106) . Like other herpesviruses, EBV has pirated and modified host genes encoding important regulatory cellular proteins to take over cellular control after infection. Although EBV was believed to be the only γ-herpesvirus that does not encode a chemokine receptor, an open reading frame within the EBV genome encoding a constitutively active GPCR, BILF1, has been identified (107, 108) . BILF1, a glycosylated protein, is expressed predominantly during lytic infection and can block protein kinase A or stimulate NF-κB activity in a pertussis toxin-sensitive manner, implying G i -dependent signaling (107, 108) .
Several functions have been attributed to BILF1 (Figure 5 ). It contributes to immune evasion during the establishment of EBV infection by physically associating with major histocompatibility complex class I (MHC-I) molecules, promoting their endocytosis and lysosomal degradation (109) . In addition, BILF1 can target newly synthesized MHC-I/peptide complexes en route to the cell surface (110) . Both mechanisms lead to the inhibition of CD8 + T cell recognition of endogenous target antigens. A BILF1 mutant unable to activate G protein signaling pathways retains the ability to downregulate MHC-I molecules, indicating that the immune-modulating and GPCRsignaling properties are distinct functions of BILF1 (111) . BILF1 is the third EBV lytic gene (along with BGLF5 and BNLF2A) that interferes with MHC-I antigen processing, implying that it is important for EBV to evade CD8 + T cell responses during the lytic replication cycle (109) . The BILF1 protein of the closely related CeHV15 γ-1-herpesvirus of the Rhesus Old World primate (80% amino acid sequence identity) downregulates surface MHC-I molecules, as does EBV BILF1, but KSHV vGPCR (the human herpesvirus-encoded GPCR most closely related to EBV BILF1, with 15% amino acid sequence identity) does not affect levels of surface MHC-I molecules (111) . BILF1 also blocks the phosphorylation of RNA-dependent protein kinase (PKR) (107) ; this blocking inhibits PKR function and may help prevent a cellular antiviral response, thereby aiding in EBV infection.
BILF1 is an orphan GPCR, as no endogenous ligand has been identified. Instead, recent evidence suggests that BILF1 can heterodimerize with host chemokine receptors and modify their signaling (112) . In particular, BILF1 can form hetero-oligomeric complexes with CXCR4, 12 inhibiting CXCL12 binding and CXCL12-induced signaling (113) . BILF1-mediated CXCR4 inhibition is a consequence of its constitutive activity, suggesting a functional cross-regulation of GPCRs by BILF1 at the level of the G proteins (perhaps by scavenging Gα i proteins). Impairment of CXCR4 function by BILF1 may control the responsiveness of B lymphocytes to chemokines, thereby altering homing and homeostasis of infected B lymphocytes; this altered homing and homeostasis, in turn, may contribute to EBV dissemination and EBV-induced pathogenesis. In addition, BILF1 has transforming potential, an effect that depends on its constitutive activity (114) . Like expression of KSHV vGPCR, BILF1 induces VEGF secretion in a constitutively active manner. These data suggest that BILF1 could play a direct role in the pathogenesis of EBV-associated malignancies, supporting the idea that inverse agonists for BILF1 might be useful for treating such cancers. EBV infection of B cells also leads to the upregulation of endogenous cellular GPCR chemokine receptors, including CCR6, CCR7, and CCR10, as well as an orphan GPCR termed BLR2/EBI1 (115) (116) (117) (118) . In addition to activating JAK-STAT signaling, induction of CCR7 activity by its endogenous ligands can stimulate AKT and ERK (119) (120) (121) . Upregulated expression of CCR7 might therefore help promote survival and proliferation of EBV-infected cells. CCR7 has also been implicated in lymphocyte migration through the activation of several Rho GTPases, including Rho, Rac, and Cdc42 (122, 123) , which may facilitate viral dissemination. In addition to EBV, HHV-6 and HHV-7 can also upregulate CCR7 expression, indicating that CCR7 may have a similar role in the pathogenesis of several herpesviruses. Nonetheless, the potential contribution of upregulation of cellular GPCRs in herpesviral diseases requires further investigation. 17.15 Changes may still occur before final publication online and in print 
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HUMAN HERPESVIRUS-6 AND HUMAN HERPESVIRUS-7 U12 AND U51
Clinically, HHV-6 (mostly variant B) has been recognized as the cause of exanthem subitum in infants and other febrile illnesses in young children (124, 125) . HHV-6 infection is widespread in infants between 6 months and 2 years of age (125, 126) . Infection is generally indolent, but it can produce an infectious-mononucleosis-like illness in some adults. Furthermore, HHV-6 reactivation in immunosuppressed patients is often associated with a worse outcome; such reactivation occurs in 33-48% of immunocompromised patients undergoing hematopoietic stem cell transplantation (127) . Clinical conditions associated with HHV-6 reactivation in this population include hepatitis, pneumonitis, bone marrow suppression, and encephalitis (124) . HHV-7 has also been associated with the development of exanthem subitum and mononucleosis-like illness, although its link to human disease is less well established.
Signaling and Pharmacology of HHV-6 and HHV-7 vGPCRs
HHV-6 and HHV-7 each encode two GPCRs, which are known as open reading frames U12 and U51. HHV-6 U12 shares distant homology with CCR3, CCR6, CCR7, and CCR9 and is a promiscuous high-affinity CC-chemokine receptor, which increases intracellular Ca 2+ concentrations through a pertussis toxin-insensitive pathway (128) . This receptor can bind the CC chemokines CCL2, CCL3, CCL4, and CCL5 (128) . The HHV-7 U12 gene also encodes a Ca 2+ -mobilizing receptor that responds to MIP3-β/CCL19, although this receptor may also bind the CC chemokines CCL17, CCL21, and CCL22 (129, 130) . The roles of these receptors and their downstream signaling events in viral disease are still obscure.
The HHV-6 U51 is distantly homologous not only to chemokine receptors, but also to receptors of the opioid family (31, 131) . HHV-6 U51 is able to bind chemokines from the CC (CCL2, CCL5, CCL7, CCL11, CCL13, CCL19, and CCL22), CX3C (CX3CL1), and XC (XCL1) families, as well as the KSHV-encoded chemokine vCXCL2/vMIP-II (131, 132) . In contrast, HHV-7 U51 binds only chemokines from the CC family (CCL17, CCL19, CCL21, and CCL22) (130) . HHV-6 U51 has constitutive signaling activity via the activation of G q and G i proteins (133) . However, the activity and coupling specificity of this receptor can be modulated by chemokine binding. CCL5 increases the activation of both the G q and G i initiated pathways, but CCL2 and CCL11 likely favor an active conformation of the HHV-6-encoded vGPCR that couples to G i proteins and diminishes G q coupling (133) . These observations support the emerging view that ligand binding can bias the signaling selectivity of GPCRs, likely depending on the access of the different G protein subunits to the conformation adopted by the GPCR bound to each of its ligands.
HHV-6 vGPCR and Immune Evasion
HHV-6 U51 expression in epithelial cells may contribute to immune evasion by causing transcriptional downregulation of the CCL5/RANTES gene and the scavenging of CCL5/RANTES protein (131) . Regulation of RANTES levels may alter the recruitment of circulating inflammatory cells that the virus can infect and thus may contribute to systemic spread of the virus from initial sites of infection; alternatively, chemokine regulation could modulate a protective inflammatory response to aid the spread of virus (131) . In addition, HHV-6 U51 induces downregulation of FOG-2, a hematopoietic transcriptional repressor that is involved in the development of Th1 and Th2 immune responses and that has been found by microarray analysis to be restricted to targets of infection and immunity in human leukocytes (132) . Stable expression of an shRNA for HHV-6 U51 in human T cells prior to infection with HHV-6 reduces viral DNA replication (134) .
CONCLUDING REMARKS
In the process of coevolution between viruses and their human and mammalian hosts, the Herpesviridae family of viruses hijacked multiple GPCRs. Viruses have evolved to exploit these vGPCRs to their advantage, harnessing the extraordinary signaling capacity of GPCRs and redirecting normal cellular programs in order to evade immunodetection and to carry out their replicative needs. The latter includes the increased motility, growth, and survival of the infected cells, which in turn may contribute to viral pathogenesis. The unique molecular features of vGPCRs allow them to integrate into and modify host signaling pathways by physically interacting with host chemokines and G proteins as well as possibly oligomerizing with host GPCRs as well as other viral GPCRs. The study of GPCRs and GPCR-initiated signaling circuitries in viral diseases has afforded the opportunity to identify effective therapeutic options that interfere with GPCR downstream targets in order to treat human virus-associated pathologies, such as KS. The recent breakthroughs in GPCR crystallography provide knowledge of the structural determinants of GPCR ligand binding and G protein activation. We expect that this knowledge will soon present the opportunity to identify vGPCR allosteric modulators that can halt the constitutive activity of vGPCRs without affecting the normal function of host chemokine receptors. Thus, vGPCRs may represent excellent candidates for pharmacological intervention in a wide variety of human virus-associated diseases.
FUTURE ISSUES
1.
What is the precise role of vGPCRs-such as those encoded by KSHV, EBV, HHV-6/HHV-7, and the HCMV viral genome-in the viral cycle and viral pathogenesis? 5. Can KSHV vGPCR inhibitors or allosteric modulators that halt its constitutive activity prevent KS development in immunosuppressed patients and AIDS patients? Can they be used to treat KS patients?
6. Can US28 inhibitors or allosteric modulators be developed as a therapeutic option for the treatment of HCMV-associated diseases?
7. Is there a natural or synthetic ligand for the EBV vGPCR, BILF1? Does it signal through G proteins?
8. What is the role of BILF in EBV-associated pathologies, including Burkitt's lymphoma and nasopharyngeal carcinoma?
